These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 15580148

  • 41. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 42. Another anti-TNF therapy for patients with Crohn's disease.
    Cross R.
    Inflamm Bowel Dis; 2008 Mar; 14(3):425-7. PubMed ID: 18095318
    [No Abstract] [Full Text] [Related]

  • 43. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, Hildner K, Hoffman A, Kiesslich R, Rink AD, Rau TT, Rose-John S, Kessler H, Schmidt J, Neurath MF.
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [Abstract] [Full Text] [Related]

  • 44. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T.
    Orv Hetil; 2009 Sep 20; 150(38):1773-9. PubMed ID: 19740722
    [Abstract] [Full Text] [Related]

  • 45. [Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when?].
    Gomollón F, López SG.
    Acta Gastroenterol Latinoam; 2008 Jun 20; 38(2):133-45. PubMed ID: 18697408
    [Abstract] [Full Text] [Related]

  • 46. [Biological therapies in rheumatology].
    Von Frenckell C, Malaise MG.
    Rev Med Liege; 2009 Jun 20; 64(5-6):293-300. PubMed ID: 19642462
    [Abstract] [Full Text] [Related]

  • 47. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data.
    Rubin DT, Uluscu O, Sederman R.
    Inflamm Bowel Dis; 2012 Dec 20; 18(12):2225-31. PubMed ID: 22359399
    [Abstract] [Full Text] [Related]

  • 48. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology.
    Lee TW, Fedorak RN.
    Gastroenterol Clin North Am; 2010 Sep 20; 39(3):543-57. PubMed ID: 20951917
    [Abstract] [Full Text] [Related]

  • 49. Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
    Vavricka SR, Bentele N, Scharl M, Rogler G, Zeitz J, Frei P, Straumann A, Binek J, Schoepfer AM, Fried M, Swiss IBDnet and Swiss IBD Cohort Study Group.
    Inflamm Bowel Dis; 2012 Aug 20; 18(8):1523-30. PubMed ID: 21987429
    [Abstract] [Full Text] [Related]

  • 50. Strategies targeting tumor necrosis factor in Crohn's disease.
    Sandborn WJ.
    Acta Gastroenterol Belg; 2001 Aug 20; 64(2):170-2. PubMed ID: 11475128
    [Abstract] [Full Text] [Related]

  • 51. Certolizumab pegol in the treatment of Crohn's disease.
    Ferrante M, Vermeire S, Rutgeerts P.
    Expert Opin Biol Ther; 2013 Apr 20; 13(4):595-605. PubMed ID: 23451881
    [Abstract] [Full Text] [Related]

  • 52. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
    Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN.
    Transplant Proc; 1998 Dec 20; 30(8):4126-7. PubMed ID: 9865320
    [No Abstract] [Full Text] [Related]

  • 53. Anti-TNF therapy.
    Thalayasingam N, Isaacs JD.
    Best Pract Res Clin Rheumatol; 2011 Aug 20; 25(4):549-67. PubMed ID: 22137924
    [Abstract] [Full Text] [Related]

  • 54. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G.
    BioDrugs; 2014 Apr 20; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [Abstract] [Full Text] [Related]

  • 55. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 56. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 14; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.
    Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS.
    Inflamm Bowel Dis; 2012 Apr 14; 18(4):691-6. PubMed ID: 21648022
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.